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Aim: To evaluate the effect of oral semaglutide on energy intake and appetite in sub-
jects with type 2 diabetes (T2D).
Materials and Methods: In this randomized, double-blind, placebo-controlled,
two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment
with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg)
followed by placebo, or vice versa. Energy intake was measured during an ad libitum
lunch, evening meal and snack box after a standard breakfast. Appetite ratings were
measured using a visual analogue scale after standard and fat-rich breakfasts. Other
assessments included eating and craving control (using the Control of Eating Ques-
tionnaire), and changes in body weight and composition.
Results: Following a standard breakfast, total daily ad libitum energy intake was sig-
nificantly lower (38.9%) with oral semaglutide versus placebo in 13 evaluable subjects
(estimated treatment difference, −5096.0 kJ; 95% CI –7000.0, −3192.1; P = .0001).
After a fat-rich breakfast, there were significant differences in favour of oral
semaglutide versus placebo for measures of satiety, hunger and for overall appetite
score, with no significant differences following a standard breakfast. Fewer food
cravings and better eating control were seen with oral semaglutide versus placebo.
Overall, mean body weight decreased by 2.7 kg with oral semaglutide and 0.1 kg with
placebo, mostly attributable to body fat mass loss.
Conclusion: After 12 weeks of treatment, ad libitum energy intake was lower with oral
semaglutide versus placebo, resulting in reduced body fat mass, and was associated with
increased satiety and fullness after a fat-rich breakfast, and improved eating control.
Trial registration number: NCT02773381
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1 | INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that acts via
its receptor to increase insulin and decrease glucagon secretion in a
glucose-dependent manner.1 GLP-1 receptor agonists (GLP-1RAs) not
only improve blood glucose homeostasis, but also promote weight
loss,1 an important consideration in the treatment of type 2 diabe-
tes (T2D).2
When mechanisms responsible for GLP-1–mediated weight
reduction were investigated, increased satiety and reduced food
intake were observed.3,4 From animal studies, it appears that func-
tional GLP-1 receptors in specific parts of the brain are required for
weight loss.1,5–7 Furthermore, animal studies have shown that the
GLP-1RAs, liraglutide and semaglutide, can access the specific areas
of the brain involved in appetite regulation.6,8 In rodents, semaglutide
caused weight loss without decreasing energy expenditure through an
effect on both homeostatic (appetite, hunger, satiety) as well as
hedonic (food choice, control) neural pathways.8
Semaglutide has 94% structural homology with native human
GLP-19 and was initially approved for the treatment of T2D when
given once weekly by subcutaneous (s.c.) injection. Semaglutide
s.c. once weekly increased fullness and reduced hunger and energy
intake in a study of 30 subjects with obesity.10 Oral semaglutide has
been developed as a co-formulation of semaglutide with the absorp-
tion enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate,11
and is the first oral GLP-1RA to be approved for the treatment of
T2D.12,13 Oral semaglutide has been shown to improve glycaemic
control and promote weight loss in patients with T2D in several
phase 3 studies.14–21
It was expected that the effects on appetite and energy intake,
and the mechanism responsible for weight loss, would be similar with
once-daily oral formulation as with once-weekly s.c. formulation.10
However, given the novel formulation of the orally administered
semaglutide, this required confirmation. Furthermore, the effects of
s.c. semaglutide on appetite and energy intake were studied in
patients with obesity10 and it was considered important to investigate
the effects of oral semaglutide in the intended population of patients
with T2D. In this exploratory study, we investigated the effects of oral
semaglutide on energy intake, appetite variables, food preference,
control of eating and body weight in subjects with T2D.
2 | MATERIALS AND METHODS
2.1 | Trial design
This was a single-centre, randomized, double-blind, placebo-con-
trolled, two-period cross-over phase 1 trial (NCT02773381) con-
ducted at a single study site in the UK (Covance Clinical Research
Unit Ltd, Leeds, UK) from 2 June 2016 to 19 October 2018. The trial
was undertaken in accordance with the International Conference on
Harmonisation Good Clinical Practice guidelines, the Declaration of
Helsinki and all applicable regulatory requirements. Written informed
consent was obtained from all participants before any trial-related
activities commenced.
2.2 | Trial population
Eligible subjects were male or female, aged 18-75 years, with T2D for at
least 90 days, HbA1c 6.0%-9.0%, body mass index (BMI) 20-38 kg/m
2,
stable body weight (<3 kg change during 90 days prior to screening) and
who were treated with diet and exercise and/or stable dose of metfor-
min for more than 30 days. Key exclusion criteria included a history of
chronic or acute pancreatitis; personal/family history of medullary thy-
roid carcinoma or multiple endocrine neoplasia syndrome type 2; previ-
ous major surgical gastric procedures or the presence of clinically
significant, or symptoms of, gastrointestinal disorders that may poten-
tially affect absorption; use of any medication that could interfere with
trial results; smoking or use of any nicotine products; or unusual meal
habits and special diet requirements compared with the general T2D
population, or an unwillingness to eat the food provided.
2.3 | Interventions
Two 12-week treatment periods were separated by a washout period
of 5-9 weeks (Figure S1). Eligible subjects were randomized 1:1 to
one of two treatment sequences: oral semaglutide–placebo or
placebo–oral semaglutide. The starting dose of once-daily oral
semaglutide was 3 mg (weeks 0-4), escalating to 7 mg (weeks 4-8)
then 14 mg (weeks 8-12) to help mitigate adverse gastrointestinal
effects. Participants were instructed to take the oral semaglutide tab-
let in the morning, in a fasted state, with up to 120 mL of water,
30 minutes before any food, beverage or other oral medication. Water
intake was allowed in the fasting period except from 2 hours prior to
dosing and until 30 minutes postdosing.
At the end of each treatment period there was a 4-day meal test
period at the study site during which assessments were performed,
resulting in a total treatment period for oral semaglutide 14 mg of
4 weeks and 3 days.
2.4 | Assessments and endpoints
The primary endpoint of the trial was to compare the effect of oral
semaglutide and placebo on postprandial glucose metabolism and
these results are reported separately.22 Secondary endpoints pres-
ented here are ad libitum energy intake, food preferences, subjective
ratings of appetite and palatability variables, control of eating, and
body weight and body composition. In addition, the pharmacokinetics
(reported separately)22 and safety of oral semaglutide were
investigated.
During day 1 of the in-house stay at the study site, subjects were
acclimatized to standardized meals and activity. On day 2, a 5-hour
breakfast meal test was performed with a standard breakfast of
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2.2 MJ (527 kcal; macronutrient composition: 30 energy percent-
age [E%] fat, 15 E% protein and 55 E% carbohydrate).
Subjective ratings of appetite variables (fullness, satiety, hunger
and prospective food consumption), thirst, nausea and well-being
were assessed on a 100 mm visual analogue scale (VAS; with the ends
of each line indicating the most extreme sensation that subjects have
experienced) 15 minutes before and at various time points (15, 30,
60, 90, 120, 180, 240 and 300 minutes) after the standard breakfast
meal.23 The average of the four appetite ratings was used to calculate
an overall appetite score: ([100-satiety] + [100-fullness] + hunger +
prospective food consumption)/4. Palatability (taste, visual appear-
ance and overall pleasantness) was assessed on a 100 mm VAS after
the standard breakfast meal.
A weighed homogeneous ad libitum lunch was served in excess
and subjects were given a self-served ad libitum evening meal. At both
ad libitum meals, subjects were instructed to eat until pleasantly sati-
ated. Staff at the study site weighed any remaining food, consumption
(g and kJ) was calculated and palatability assessments were per-
formed. Subjects received an evening snack box (four items of 100 g
each: high-fat and sweet; low-fat and sweet; high-fat and non-sweet;
low-fat and non-sweet; individualized by preference), which they
were allowed to keep until midnight. Study staff then weighed any
remaining snacks and the amount of each of the food categories con-
sumed was recorded.
On day 3, body weight and composition (whole body fat mass
and lean mass, and percentage body fat) were measured in a fasted
state using air displacement plethysmography (Bodpod®, Concord,
CA, USA) with determination via density measurements (body
density = body weight/body volume). Body weight was also measured
at baseline and every 4 weeks during both treatment periods using
standard weight scales. Control of eating and the degree of food crav-
ings were also measured on day 3 in a fasted state using a validated
Control of Eating Questionnaire (CoEQ),24 which included questions
related to food cravings, control of eating, hunger and fullness. Based
on the previous 7 days, subjects were asked to answer 21 questions
(20 rated on a 100 mm VAS and one open-ended). On day 4, an
8-hour meal test was performed with a fat-rich breakfast of 3.5 MJ
(844 kcal; macronutrient composition: 65 E% fat, 15 E% protein and
20 E% carbohydrate) assessing appetite and palatability.
Safety assessments included adverse events (AEs), hypoglycaemic
events and blood pressure.
2.5 | Statistical analysis
A sample size of 18 subjects was expected to give at least 90% power
to detect a difference in the primary endpoint of area under the
concentration–time curve from 0 to 5 hours after the start of the meal
(AUC0-5h) for glucose, except if there was a reduction in AUC0-5h for
glucose of less than 20% combined with a greater within-subject stan-
dard deviation (>0.19), and at least 80% power to detect a difference
in ad libitum energy intake of 856 kJ during a lunch meal with a
within-subject standard deviation of 850 kJ. As the trial had a long
duration, a total of 22 subjects were planned to be randomized to
allow for withdrawals. Further details of the sample size calculation
are provided in Appendix S1.
The difference between oral semaglutide and placebo for each
outcome was estimated and presented together with the
corresponding two-sided 95% confidence intervals (CI) and P-values
for the test of no difference (t-test). Endpoints were analysed using an
analysis of variance model, with the endpoint as dependent variable
and treatment (oral semaglutide or placebo), treatment period
(two levels) and subject as fixed factors. For the food preference end-
points of energy intake and quantity of food consumed from each of
the four food categories in the evening snack box, the model addition-
ally included interaction between treatment and fat/sweet food cate-
gories. Safety endpoints were analysed descriptively.
3 | RESULTS
3.1 | Subject characteristics
Following screening of 53 subjects, only 15 of the planned 22 subjects
were randomized. Thirteen subjects completed the trial. One male
subject was withdrawn because of an AE (acute myocardial infarction),
while one subject withdrew consent before the end of the trial
because of personal/other reasons. Baseline characteristics are shown
in Table S1. Thirteen subjects were male (86.7%). The mean age was
58.2 years, with a mean body weight of 93.9 kg and mean BMI of
30.8 kg/m2. Mean HbA1c was 6.9% and the mean duration of T2D
was 3 years.
3.2 | Energy intake
Following a standard breakfast meal, total daily energy intake during
ad libitum lunch, ad libitum evening meal and ad libitum snack box
was significantly lower with oral semaglutide than with placebo (rela-
tive difference −38.9%; estimated treatment difference [ETD],
−5096.0 kJ; 95% CI, −7000.0, −3192.1; P = .0001) (Figure 1A).
Energy intake for all four food categories in the snack box tended
to be lower with oral semaglutide than with placebo, but was signifi-
cantly lower for the categories ‘high fat and sweet’, ‘high fat’ and
‘sweet’ (Figure 1B). For high-fat sweet foods, mean energy intake was
1431.0 kJ with oral semaglutide compared with 2336.7 kJ with pla-
cebo (ETD, −905.7 kJ; 95% CI, −1538.5, −272.9; P = .0055). For high-
fat non-sweet foods, mean energy intake was 577.6 kJ with oral
semaglutide compared with 1053.7 kJ with placebo (ETD, −476.2 kJ;
95% CI, −1109.0, 156.6; P = .1384). For low-fat sweet foods, mean
energy intake was 899.8 kJ with oral semaglutide compared with
1301.9 kJ with placebo (ETD, −402.1 kJ; 95% CI, −1034.9, 230.7;
P = .2100). For low-fat non-sweet foods, mean energy intake was
328.9 kJ with oral semaglutide compared with 518.2 kJ with placebo
(ETD, −189.3 kJ; 95% CI, −822.1, 443.5; P = .5537). Overall, energy
intake from high-fat foods was 2008.6 kJ when subjects were treated
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with oral semaglutide, and 3390.4 kJ when subjects were receiving
placebo (ETD, −1381.9 kJ; 95% CI, −2248.6, −515.1; P = .0026).
3.3 | Appetite, palatability and control of eating
VAS scores for subjective fasting ratings of appetite were not signifi-
cantly different between oral semaglutide and placebo before the
standard breakfast and 0-5 hours after the standard breakfast
(Figure 2A; Figure S2). After the fat-rich breakfast, there were signifi-
cant differences in favour of oral semaglutide versus placebo for the
mean postprandial overall appetite score, as well as all four individual
mean postprandial ratings of satiety, fullness, hunger and prospective
food consumption (Figure 2B; Figure S3). Overall appetite scores
remained lower at all time points with oral semaglutide compared with
placebo, particularly after the fat-rich breakfast (Figure S3).
Palatability (taste, visual appearance and overall pleasantness) of
the breakfasts, ad libitum lunch and evening meal, and evening snack
box appeared similar for oral semaglutide and placebo (Table S2). No
mean VAS scores of less than 50 mm were reported for palatability
with either treatment, indicating no general food aversion.
When control of eating was evaluated with the CoEQ after a
standard breakfast, there were significant differences in four out of
the 20 closed questions indicating fewer and less strong food crav-
ings, better control of eating and less difficulty resisting food when
receiving oral semaglutide versus placebo (Figure S4).
3.4 | Body weight and composition
Overall, for both treatment periods, mean body weight (as measured
by Bodpod®) decreased by 2.7 kg with oral semaglutide and 0.1 kg
F IGURE 1 Energy intake during A, all ad libitum meals and B, ad libitum snack box. Values are estimated means. Relative difference:
estimated treatment difference (ETD)/estimated mean for placebo × 100%. Data in bold indicate significant difference (P < .05) between
treatment groups. CI, confidence interval
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F IGURE 2 Mean fasting and postprandial appetite ratings after A, standard breakfast and B, fat-rich breakfast. A, after standard breakfast:
mean postprandial rating = AUC15–300 min/285 min (postprandial time span). Overall appetite score = ([100-satiety] + [100-fullness] + hunger +
prospective food consumption)/4; B, after fat-rich breakfast:mean postprandial rating = AUC15–480 min/465 min (postprandial time span). Overall
appetite score = ([100-satiety] + [100-fullness] + hunger + prospective food consumption)/4. Values are estimated means. Data in bold indicate
significant difference (P < .05) between treatment groups.AUC, area under the concentration–time curve; CI, confidence interval; ETD, estimated
treatment difference; VAS, visual analogue scale
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with placebo (Table 1). Weight loss with oral semaglutide was attrib-
utable to a 2.6 kg reduction in whole body fat mass, whereas whole
body lean mass was not reduced. Mean fat percentage was reduced
by 2.0% with oral semaglutide and by 0.8% with placebo (Table 1).
Changes in body weight from baseline over time in subjects complet-
ing the trial are shown in Figure S5. For subjects receiving oral
semaglutide, a similar decrease in body weight was seen in both
treatment periods. For subjects receiving placebo in the first treat-
ment period, body weight remained near baseline during the entire
12-week treatment period. For subjects receiving placebo during the
second 12-week treatment period, there was a rebound increase in
body weight after the end of the first oral semaglutide treatment
period. The washout period between treatments was of insufficient
duration for body weight to return to baseline level and weight gain
continued on placebo during the second treatment period, returning
to near baseline. A similar rebound effect was seen with waist cir-
cumference measurements. Across both treatment periods, mean
observed waist circumference decreased with both oral semaglutide
(2.4 cm) and placebo (2.0 cm). In subjects receiving placebo during
the first treatment period, waist circumference decreased, then
increased during the washout period, before decreasing with oral
semaglutide during the second 12-week treatment period. For sub-
jects receiving oral semaglutide during the first 12-week treatment
period, there was a rebound increase in waist circumference in the
washout period that continued on placebo during the second
12-week treatment period.
3.5 | Safety
More AEs were reported in subjects when receiving oral semaglutide
versus placebo (93 events in 14 [93.3%] subjects vs. 51 events in
13 [92.9%] subjects) (Table S3). Typical of the GLP-1RA class, gastro-
intestinal AEs were more frequently reported with oral semaglutide
(47 events in 10 [66.7%] subjects) than with placebo (17 events in
7 [50.0%] subjects) (Table S3). The apparent difference in the number
of events between oral semaglutide versus placebo treatments was
primarily driven by subjects reporting nausea (11 vs. three events),
vomiting (six vs. one event), abdominal pain (six vs. one event), eructa-
tion (three vs. no events) and flatulence (four vs. no events).
There was one serious AE (acute myocardial infarction), which
occurred during treatment with oral semaglutide; this was considered
a severe AE and led to trial withdrawal. All other AEs reported were
of mild or moderate severity. No deaths were reported. There were
no clinically relevant changes in vital signs including blood pressure
(systolic and diastolic), pulse rate and body temperature.
4 | DISCUSSION
The main finding reported here was that ad libitum energy intake
throughout the day was lower during treatment with oral semaglutide
than with placebo in subjects with T2D. These findings are consistent
with our previous study that found a similarly lower ad libitum energy
intake following 12 weeks of treatment with s.c. once-weekly
semaglutide versus placebo in 30 subjects with obesity.10 Thus, it
appears that the effects of semaglutide are similar whether given by
once-weekly s.c. injection or via the novel once-daily oral formulation
and in patients with obesity10 or T2D.
Of note, the lower energy intake seen with semaglutide was asso-
ciated with changes in food preferences and feelings of appetite con-
trol. In the evening snack box assessment, the lower preference for
high-fat snacks with oral semaglutide versus placebo was significant.
In addition, there was also less preference for sweet foods with oral
semaglutide than placebo. A lower preference for high-fat food was
also seen in the trial with s.c. semaglutide, where the Leeds Food Pref-
erence Questionnaire indicated a significantly lower explicit liking for
high-fat and non-sweet foods with s.c. semaglutide versus placebo.10
Furthermore, ratings of implicit wanting were significantly lower for
high-fat and non-sweet foods and higher for low-fat and sweet foods
with s.c. semaglutide versus placebo.
In the current study, the reduced food intake and the associated
weight loss did not appear to induce a compensatory increase in the
drive to eat. In fact, mean postprandial overall appetite score (includ-
ing all four individual ratings of satiety, fullness, hunger and prospec-
tive food consumption) was more favourable following treatment with
oral semaglutide versus placebo, indicating reduced appetite and
improved satiety with oral semaglutide, but these differences were
more prominent after the fat-rich, high-calorie breakfast and not the
standard lower-calorie breakfast.
Overall appetite scores remained lower at all time points with oral
semaglutide compared with placebo after both the standard and fat-
rich breakfasts, although these only reached statistical significance
after the fat-rich breakfast. These findings are largely consistent with
those previously observed for s.c. semaglutide in obese subjects, in
which the fasting overall appetite suppression score was significantly
higher with semaglutide versus placebo after a standard breakfast
(not assessed after fat-rich breakfast).10 It should be noted that in the
TABLE 1 Changes from baseline in body weight and body
composition as measured by Bodpod® and waist circumference at
week 12 (day 3)
Mean ± standard deviation
Oral
semaglutide (N = 13)
Placebo
(N = 14)
Body weight, kg −2.7 ± 3.6 −0.1 ± 2.7
Whole body fat mass,
kg
−2.6 ± 2.5 −0.6 ± 2.6
Whole body lean mass,
kg
−0.1 ± 1.7 0.5 ± 1.2
Fat percentage −2.0 ± 1.8 −0.8 ± 2.2
Waist circumference,
cm
−2.4 ± 2.1 −2.0 ± 4.7
Abbreviation: N, number of subjects contributing to the summary statistic.
Note: Values are observed means.
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current trial, an overall appetite score was prespecified, whereas the
trial with s.c. semaglutide reported the inverse (i.e. overall appetite
suppression score). The reason for selecting the appetite score in this
trial was that it was considered more intuitive to investigate the
change in appetite as opposed to appetite suppression.
Control of eating was improved during treatment with oral
semaglutide compared with placebo, which is in line with findings with
s.c. semaglutide.10 With both oral and s.c. administered semaglutide
versus placebo, palatability ratings were similar and all mean ratings
were above 50 mm for both treatments, indicating that meals were
well liked. Thus, it appears that nausea or food aversion were not the
cause of the lower energy intake.
Reduced appetite and energy intake, with less preference for
energy-rich foods, provides a possible mechanism to explain the
weight loss observed with oral semaglutide. Treatment with oral
semaglutide over 12 weeks led to weight reductions of 2.7 kg in this
trial, which is consistent with a weight loss of 3.3-4.7 kg observed
over 26 weeks with oral semaglutide 14 mg in phase 3 trials.14–18,20
In the current study, body weight reductions were mainly driven by
reductions in body fat mass, which was also seen in the study with
s.c. semaglutide. Long-term effects on body weight were seen in
phase 3 trials with oral semaglutide, suggesting that the proposed
mechanism is clinically relevant, helping to maintain sustainable
weight loss, an important attribute in the overall management of T2D.
Greater body weight reductions were seen in the s.c. semaglutide trial
(5.0 kg) than with oral semaglutide, but this may reflect the different
populations studied (obese vs. T2D). Although acting as subjects' own
controls is a strength of the cross-over design for most variables, in
the current study the cross-over limited weight loss and waist circum-
ference assessments. The changes for subjects when treated with pla-
cebo should be interpreted with caution because of the rebound
effect of subjects treated with oral semaglutide in the first treatment
period. A longer washout period may have avoided this.
Regarding safety, as expected there were more AEs with oral
semaglutide than placebo, which were mostly mild or moderate gas-
trointestinal AEs. One serious AE of acute myocardial infarction was
reported in a subject with underlying risk factors of longstanding T2D,
hypertension, prior hypercholesterolaemia and obesity. Overall, the
safety profile of oral semaglutide from the phase 3 PIONEER pro-
gramme is consistent with the GLP-1RA class as a whole.14–21 This
includes cardiovascular safety, with several GLP-1RAs including s.c.
semaglutide having a proven CV benefit.25 Exposure of semaglutide,
which is reported elsewhere,22 was consistent with previously publi-
shed data.26
A limitation of the trial is that the power to detect differences
was reduced as only 15 of the planned 22 subjects were random-
ized. However, the results are generally consistent with the find-
ings of the previous trial for s.c. semaglutide in 30 subjects with
obesity.10 In addition, the results were comparable for the two dif-
ferent populations in each trial. A further limitation was the short
duration of the treatment period, which may not have been suffi-
cient to determine if there was a plateau effect on body weight
with oral semaglutide. In addition, the trial population was mostly
male and entirely white, and may not be representative of the gen-
eral population. No adjustments of hypothesis tests for multiplicity
were performed; rather, this exploratory trial was intended to gen-
erate evidence on possible mechanisms. As a broad scope of food-
related endpoints was studied, there is a risk of false positive
findings.
In conclusion, ad libitum energy intake throughout the day was
lower during treatment with oral semaglutide versus placebo. The
reduced food intake observed with oral semaglutide did not result in
an increased desire to eat, but instead was associated with improved
eating control, satiety and fullness, and reduced hunger and prefer-
ence for energy-dense foods, resulting in a greater reduction in body
weight after 12 weeks of treatment, mainly accounted for by a reduc-
tion in whole body fat mass. These findings provide a possible mecha-
nism for the sustained weight loss seen with oral semaglutide in phase
3 trials.
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